

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/265413247>

# Anti-inflammatory activities of some newly synthesized substituted thienochromene and Schiff base derivatives

ARTICLE · AUGUST 2013

---

READS

26

1 AUTHOR:



Mohamed Sakran

Tanta University

15 PUBLICATIONS 19 CITATIONS

SEE PROFILE

# Anticancer activity of some newly synthesized pyrano [2,3-d][1,2,3]triazine derivatives using 1-(7-hydroxy-2,2-dimethylchroman-6-yl)ethanone as synthon

Nabil H. Ouf · Abd El-Galil E. Amr ·  
Mohamed I. Sakran

Received: 3 October 2013 / Accepted: 11 August 2014  
© Springer Science+Business Media New York 2014

**Abstract** A series of the newly substituted pyrano[1,2,3]triazine derivatives **3–14** were synthesized using compounds **1** and **2** as starting materials. Compound **2** was methylated using methyl iodide to compound **3**, which was treated with aromatic aldehydes to give acryloyl derivatives **4a–c**. Compounds **4a,b** were reacted with ethyl cyano-acetate to give pyran-3-carboxylates **5a,b** which were reacted with ethyl glycinate hydrochloride to give **6a,b**. Treatment of **6a,b** with hydrazine hydrate gives acid hydrazides **7a,b**, which were reacted with 5,5-dimethyl-1,3-cyclohexanedione to give acetohydrazides **8a,b**. Cyclization of **8b** with 2-(4-nitrobenzylidene)malononitrile afforded hexahydroquinoline **9**. However, the acridindione **10** was synthesized by heating of **8b** with 2-(4-nitrobenzylidene)malononitrile in acetic acid containing few drops of triethylamine. Treatment of **7a,b** with phenyl isothiocyanate or 2,5-hexanedione or phthalic anhydride gave compounds **11a,b**, **13a,b** and **14a,b**, respectively.

In the present work, all the selected pyrano[1,2,3]triazine derivatives were soluble in DMSO at concentrations high enough to allow cell experiments, and the in vitro biological activity of these compounds was evaluated by their growth inhibitory potency in liver HEPG2 cancer cell lines. The cytotoxic potency of compounds **3–14** was studied in comparison to the known anticancer drugs 5-fluorouracil and doxorubicin.

**Keywords** 1-(2,4-Dihydroxyphenyl)ethanone · Acryloyl derivatives · Pyrano[1,2,3]triazine · Anticancer and cytotoxic activities

## Introduction

A number of derivatives containing s-triazine nucleus have been reported as heterocyclic compounds (Smith *et al.*, 1980). They are applicable as reactive dyes and also are used as polymers and drugs (Chaudhari and Patel, 2010; Halverson and Hirt, 1951). Among the compound having good antimicrobial properties, s-triazine derivatives constitute an important class of compounds possessing diverse pharmacological activities including broadly active as herbicidal (Gamez *et al.*, 2003) and antimicrobial (Jain *et al.*, 2007). Some are also used for the treatment of HIV infection (Patel *et al.*, 2007). Several workers investigated the s-triazine nucleus in the scope of potential therapeutic agents for diseases due to bacteria (Srinivas *et al.*, 2006), cancer (Kaswala *et al.*, 2009), and antitumor (Shin-ichi *et al.*, 2006). As pyrimidine is basic nucleus in DNA and RNA, it has been found to associate with diverse pharmacological activities such as anticancer (Patel *et al.*, 2001), anti-inflammatory (Vanderhoek *et al.*, 1973), antiviral (Patel *et al.*, 2012), antibacterial (Karci *et al.*, 2009; Modha *et al.*, 2001), antioxidant (Sharma and Reddy, 1993),

N. H. Ouf (✉) · M. I. Sakran  
Department of Chemistry and Biochemistry, Faculty of Science,  
Tabuk University, Tabuk, Saudi Arabia  
e-mail: ouf.nabil@yahoo.com

N. H. Ouf  
Department of Chemistry, Faculty of Science,  
Zagazig University, Zagazig, Egypt

A. E.-G. E. Amr  
Pharmaceutical Chemistry Department, College of Pharmacy,  
King Saud University, Riyadh 11451, Saudi Arabia

A. E.-G. E. Amr  
Applied Organic Chemistry Department, National Research  
Center, Dokki, Cairo, Egypt

M. I. Sakran  
Department of Chemistry, Faculty of Science, Tanta University,  
Tanta 31527, Egypt

antiulcer (Laner *et al.*, 1998), and anti-HIV/AIDS (Patel *et al.*, 2007) activities. Additionally, in our previous work, we reported the synthesis of substituted heterocyclic derivatives as anti-inflammatory (Amr *et al.*, 2005) and antitumor (Abo-Ghalia and Amr, 2004 and Hammam *et al.*, 2003) agents. On the other hand, pyrimidine and thiazolopyrimidine derivatives have promising biological and anticancer activities (Girgis and Ahmed-Farag, 2003 and Flefel *et al.*, 2007). Also, the newly substituted heterocyclic candidates exhibited antian-drogenic (Amr and Abdalla, 2006), analgesic, antiparkinsonian, anti-inflammatory (Amr and Abdalla, 2006; Ouf *et al.*, 2008 and Ouf and Amr, 2008), anticancer (Amr *et al.*, 2006a, 2006b), anticonvulsant (Nehad *et al.*, 2007), and antiarhythmic (Ahmed *et al.*, 2007) activities. In view of these observations and in continuation of our previous work in heterocyclic chemistry, we synthesized some new pyrano[2,3-d][1,2,3]triazine derivatives and tested their anticancer activities with 5-fluorouracil (5-FU) and doxorubicin (DOX) as anticancer drugs.

## Materials and methods

### Chemistry

All melting points were taken on Electrothermal IA 9000 series digital melting point apparatus. Elemental analysis data were obtained from the microanalytical unit, Cairo University, Cairo, Egypt, and the results were in favorable agreements with the calculated values. The IR spectra (KBr) were recorded on a PYEUNICAM spectrophotometer. The  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectra were recorded at 300 MHz on a Perkin Elmer R12B Spectrometer using TMS as an internal standard. The mass spectra were performed using VG 2AB-3F spectrometer (70 eV). All reactions were followed by TLC (silica gel, aluminum sheets 60F<sub>254</sub>, Merck). The starting materials **1** and **2** were prepared according to the reported procedures (Kumar *et al.*, 2011).

#### *1-(7-Methoxy-2,2-dimethylchroman-6-yl)ethanone (3)*

A mixture of compound **2** (2 g), methyl iodide (7 mL), and anhydrous potassium carbonate (7 g) in acetone (100 mL) was refluxed for 12 h and then filtered while hot. The filtrate solution was evaporated under reduced pressure to dryness, and the obtained residue was crystallized from ethanol to give compound **3** as yellow powder. Yield 75 %, m.p. 117 °C; IR (KBr,  $\text{cm}^{-1}$ ): 1667 (C=O), 2995 (CH-Aliph.), 3080 (CH-Ar), 1223 (C–O ether);  $^1\text{H}$ -NMR (DMSO- $d_6$ , 300 MHz):  $\delta$  = 1.50 (d, 6H, 2CH<sub>3</sub>), 2.00–2.42 (m, 4H, 2CH<sub>2</sub>), 2.50 (s, 3H, COCH<sub>3</sub>), 3.84 (s, 3H, OCH<sub>3</sub>), 6.65, 7.58 (2 s, 2H, Ar–H);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ ,

67.5 MHz):  $\delta$  =  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.45, 28.15 (3CH<sub>3</sub>), 55.65 (OCH<sub>3</sub>), 198.45 (C=O), 76.32 (C-1), 32.05 (C-2), 22.98 (C-3), 116.68 (C-4), 128.92 (C-5), 110.75 (C-6), 156.96 (C-7), 100.01 (C-8), 159.48 (C-9); MS (EI, 70 eV):  $m/z$  = 234 [ $\text{M}^+$ , 100]. Anal. calcd. for C<sub>14</sub>H<sub>18</sub>O<sub>3</sub> (234.29): C, 71.77; H, 7.74. Found: C, 71.74; H, 7.70.

#### *(E)-3-(Aryl)-1-(7-methoxy-2,2-dimethylchroman-6-yl)prop-2-en-1-one 4a-c*

A mixture of compound **3** (0.01 mol) and aromatic aldehydes, namely, vanillin, benzaldehyde, or 3-anisaldehyde, in the presence of two drops of piperidine was heated under reflux for 2–4 h. The reaction mixture was cooled and triturated with ethanol then filtered off, dried, and then crystallized from propan-2-ol to give compounds (**4a–c**), respectively.

#### *(E)-3-(4-Hydroxy-3-methoxyphenyl)-1-(7-methoxy-2,2-dimethylchroman-6-yl)prop-2-en-1-one (4a)*

Brown powder, yield 70 %, m.p. 197 °C; IR (KBr,  $\text{cm}^{-1}$ ): 1667 (C=O), 3433 (OH);  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.52 (d, 6H, 2CH<sub>3</sub>), 1.98–2.38 (m, 4H, 2CH<sub>2</sub>), 3.71, 4.03 (2 s, 6H, 2OCH<sub>3</sub>), 5.36 (s, 1H, OH, exchangeable with D<sub>2</sub>O), 6.84–7.39 (m, 7H, 5H Ar–H + CH=CH);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.42 (2CH<sub>3</sub>), 55.85, 56.02 (2OCH<sub>3</sub>), 76.42 (C-1), 31.93 (C-2), 22.65 (C-3), 117.24 (C-4), 129.18 (C-5), 111.64 (C-6), 157.96 (C-7), 100.45 (C-8), 159.68 (C-9), 189.22 (C-10), 120.88 (C-11), 144.35 (C-12), 128.45 (C-13), 119.78 (C-14), 115.98 (C-15), 144.15 (C-16), 151.05 (C-17), 111.95 (C-18); MS (EI, 70 eV):  $m/z$  = 368 [ $\text{M}^+$ , 8] and at 178 (100, base peak). Anal. calcd. for C<sub>22</sub>H<sub>24</sub>O<sub>5</sub> (368.42): C, 71.72; H, 6.57. Found: C, 71.65; H, 6.52.

#### *(E)-1-(7-Methoxy-2,2-dimethylchroman-6-yl)-3-phenylprop-2-en-1-one (4b)*

Brown powder, yield 70 %, m.p. 220 °C; IR (KBr,  $\text{cm}^{-1}$ ): 1680 (C=O), 2990 (CH-aliphatic), 3090 (CH aromatic), 1220 (C–O ether);  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.48 (d, 6H, 2CH<sub>3</sub>), 2.05–2.48 (m, 4H, 2CH<sub>2</sub>), 3.92 (s, 3H, OCH<sub>3</sub>), 7.33–8.06 (m, 9H, 7H Ar–H + CH=CH);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.36 (2CH<sub>3</sub>), 55.864 (OCH<sub>3</sub>), 76.45 (C-1), 32.04 (C-2), 22.58 (C-3), 118.22 (C-4), 129.32 (C-5), 112.05 (C-6), 158.54 (C-7), 101.00 (C-8), 160.64 (C-9), 189.45 (C-10), 120.82 (C-11), 144.48 (C-12), 135.15 (C-13), 127.03 (C-14, C-18), 127.98 (C-15, C-17), 127.68 (C-16); MS (EI, 70 eV):  $m/z$  = 322 [ $\text{M}^+$ , 12] and at 132 (100, base peak). Anal. calcd. for C<sub>21</sub>H<sub>22</sub>O<sub>3</sub> (322.40): C, 78.23; H, 6.88. Found: C, 78.18; H, 6.82.

*(E)*-1-(7-Methoxy-2,2-dimethylchroman-6-yl)-3-(3-methoxyphenyl)prop-2-en-1-one (**4c**)

Crystallized from pale yellow powder, yield 80 %, m.p. 302 °C; IR (KBr,  $\text{cm}^{-1}$ ): 1670 (C=O), 2992 (CH-aliphatic), 3090 (CH aromatic), 1225 (C–O ether);  $^1\text{H-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 1.48 (d, 6H, 2CH<sub>3</sub>), 1.96–2.42 (m, 4H, 2CH<sub>2</sub>), 3.75, 3.92, (2 s, 6H, 2OCH<sub>3</sub>), 7.61–8.06 (m, 8H, 6H Ar–H + CH=CH);  $^{13}\text{C-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 27.35 (2CH<sub>3</sub>), 55.76, 56.05 (2OCH<sub>3</sub>), 76.45 (C-1), 31.92 (C-2), 22.54 (C-3), 117.32 (C-4), 130.02 (C-5), 111.72 (C-6), 158.65 (C-7), 100.32 (C-8), 160.38 (C-9), 188.99 (C-10), 121.18 (C-11), 144.65 (C-12), 136.01 (C-13), 118.02 (C-14), 129.06 (C-15), 113.12 (C-16), 160.22 (C-17), 110.08 (C-18); MS (EI, 70 eV):  $m/z$  = 352 [ $\text{M}^+$ , 18] and at 162 (100, base peak). Anal. calcd. for C<sub>22</sub>H<sub>24</sub>O<sub>4</sub> (352.44): C, 74.98; H, 6.86. Found: C, 74.95; H, 6.80.

*Ethyl 2-amino-4-(aryl)-6-(7-methoxy-2,2-dimethylchroman-6-yl)-4H-pyran-3-carboxylate (5a,b)*

A mixture of compound **4a** or **4b** (1 mmol) and ethyl cyanoacetate (1 mmol) in pyridine (50 mL) was refluxed for 12 h. The reaction mixture was poured into ice water and neutralized with hydrochloric acid, and the obtained precipitate was filtered off, washed with water, dried, and crystallized from propan-2-ol to give compounds **5a,b**, respectively.

*Ethyl 2-amino-4-(4-hydroxy-3-methoxyphenyl)-6-(7-methoxy-2,2-dimethylchroman-6-yl)-4H-pyran-3-carboxylate (5a)*

Pale yellow powder, yield 85 %, m.p. 106 °C; IR (KBr,  $\text{cm}^{-1}$ ): 1735 (CO, ester), 3375 (OH), 3129, 3153 (NH<sub>2</sub>);  $^1\text{H-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 1.37 (t, 3H, CH<sub>3</sub>), 1.52 (d, 6H, 2CH<sub>3</sub>), 2.00–2.52 (m, 4H, 2CH<sub>2</sub>), 3.88, 3.98 (2 s, 6H, 2OCH<sub>3</sub>), 4.33 (q, 2H, CH<sub>2</sub>), 4.46 (s, 1H, pyrane-CH), 5.72 (s, 1H, OH, exchangeable with D<sub>2</sub>O), 6.98–7.85 (m, 6H, Ar–H + CH-pyrane), 8.14 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O);  $^{13}\text{C-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 14.05 (CH<sub>3</sub>-ester), 27.05 (2CH<sub>3</sub>), 56.10, 56.18 (2OCH<sub>3</sub>), 61.45 (CH<sub>2</sub>-ester), 166.86 (C=O, ester), 76.32 (C-1), 32.06 (C-2), 23.16 (C-3), 117.25 (C-4), 127.22 (C-5), 101.52 (C-6), 155.18 (C-7), 99.98 (C-8), 154.86 (C-9), 140.26 (C-10), 91.08 (C-11), 39.76 (C-12), 75.62 (C-13), 162.05 (C-14), 135.72 (C-15), 122.65 (C-16), 116.02 (C-17), 142.20 (C-18), 151.10 (C-19), 114.01 (C-20); MS (EI, 70 eV):  $m/z$  = 481 [ $\text{M}^+$ , 22] and at 246 (100, base peak). Anal. calcd. for C<sub>27</sub>H<sub>31</sub>NO<sub>7</sub> (481.53): C, 67.34; H, 6.49; N, 2.91. Found: C, 67.28; H, 6.40; N, 2.89.

*Ethyl 2-amino-6-(7-methoxy-2,2-dimethylchroman-6-yl)-4-phenyl-4H-pyran-3-carboxylate (5b)*

Pale yellow powder, yield 70 %, m.p. 113 °C; IR (KBr,  $\text{cm}^{-1}$ ): 1732 (CO, ester), 3132, 3389 (NH<sub>2</sub>).  $^1\text{H-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 1.26 (t, 3H, CH<sub>3</sub>), 1.50 (d, 6H, 2CH<sub>3</sub>), 1.98–2.40 (m, 4H, 2CH<sub>2</sub>), 3.83 (s, 3H, OCH<sub>3</sub>), 4.23 (q, 2H, CH<sub>2</sub>), 4.46 (s, 1H, CH-pyrane), 6.99–7.50 (m, 8H, Ar–H + CH-pyrane), 7.95 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O);  $^{13}\text{C-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 14.07 (CH<sub>3</sub>-ester), 27.10 (2CH<sub>3</sub>), 56.12 (OCH<sub>3</sub>), 61.36 (CH<sub>2</sub>-ester), 166.84 (C=O, ester), 76.38 (C-1), 32.10 (C-2), 23.15 (C-3), 117.36 (C-4), 127.18 (C-5), 101.48 (C-6), 155.16 (C-7), 99.99 (C-8), 154.82 (C-9), 140.24 (C-10), 91.00 (C-11), 39.75 (C-12), 75.60 (C-13), 162.08 (C-14), 142.01 (C-15), 122.65 (C-16), 116.02 (C-17), 142.20 (C-18), 151.10 (C-19), 114.01 (C-20); MS (EI, 70 eV):  $m/z$  = 435 [ $\text{M}^+$ , 24] and at 390 (100, base peak). Anal. calcd. for C<sub>26</sub>H<sub>29</sub>NO<sub>5</sub> (435.51): C, 71.70; H, 6.71; N, 3.22. Found: C, 71.65; H, 6.67; N, 3.15.

*Ethyl 2-(aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]-triazin-3(5H)-yl)acetate (6a,b)*

To a solution of ethyl carboxylate **5a** or **5b** (6 g, 0.039 mol) cooled solution of dilute hydrochloric acid, a solution of sodium nitrite (4.25 g) in water (10 ml) was added to form diazonium salt. A solution of ethyl glycinate hydrochloride (5.54 g, 0.039 mol) was added to the stirred solution of the diazonium salt with subsequent neutralization by sodium carbonate. After 1 h stirring, the obtained precipitate was separated by filtration, and the formed solid was washed with water, air-dried, and crystallized from absolute ethanol to give compounds **6a** or **6b**.

*Ethyl 2-(5-(4-hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetate (6a)*

Yield: 86 %, m.p. 226 °C; IR (KBr,  $\text{cm}^{-1}$ ): 3380 (OH), 3050 (C–H Ar.), 2965 (C–H aliph.), 1739 (C=O, ester), 1680 (C=O, amidic), 1233 (C–O);  $^1\text{H-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 1.36 (t, 3H, CH<sub>3</sub>), 1.54 (d, 6H, 2CH<sub>3</sub>), 2.02–2.46 (m, 4H, 2CH<sub>2</sub>), 3.80, 3.86 (2 s, 6H, OCH<sub>3</sub>), 4.30 (q, 2H, CH<sub>2</sub>), 4.38 (s, 1H, CH-pyrane), 4.68 (s, 2H, CH<sub>2</sub>), 5.70 (s, 1H, OH exchangeable with D<sub>2</sub>O), 6.86–7.72 (m, 6H, Ar–H + CH-pyrane);  $^{13}\text{C-NMR}$  (DMSO- $d_6$ , ppm):  $\delta$  = 14.05 (CH<sub>3</sub>-ester), 27.48 (2CH<sub>3</sub>), 56.15, 56.28 (2OCH<sub>3</sub>), 61.45 (CH<sub>2</sub>-ester), 168.65 (C=O, ester), 76.32 (C-1), 31.92 (C-2), 23.18 (C-3), 116.52 (C-4), 127.26 (C-5), 100.96 (C-6), 154.95 (C-7), 100.18 (C-8), 154.64 (C-9),

140.32 (C-10), 91.36 (C-11), 40.34 (C-12), 114.75 (C-13), 147.56 (C-14), 135.35 (C-15), 121.86 (C-16), 116.08 (C-17), 142.22 (C-18), 151.12 (C-19), 114.16 (C-20), 158.72 (C-21), 48.55 (C-22); MS (EI, 70 eV):  $m/z$  = 550 [ $M^+$ , 4] and at 192 (100, base peak). Anal. calcd. for  $C_{29}H_{31}N_3O_8$  (549.57): C, 63.38; H, 5.69; N, 7.65. Found: C, 63.30; H, 5.65; N, 7.60.

*Ethyl 2-(7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetate (6b)*

Yield: 65 %, m.p. 205 °C; IR (KBr,  $cm^{-1}$ ): 3050 (C–H Ar.), 2965 (C–H aliph.), 1739 (C=O, ester), 1680 (C=O, amidic), 1233 (C–O);  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  1.38 (t, 3H,  $CH_3$ ), 1.48 (d, 6H,  $2CH_3$ ), 1.98–2.42 (m, 4H,  $2CH_2$ ), 3.92 (s, 3H,  $OCH_3$ ), 4.32 (q, 2H,  $CH_2$ ), 4.45 (s, 1H, CH-pyrane), 4.70 (s, 2H,  $CH_2$ ), 6.82–7.76 (m, 8H, Ar–H + CH-pyrane);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 14.05 ( $CH_3$ -ester), 27.48 ( $2CH_3$ ), 56.15 ( $OCH_3$ ), 61.45 ( $CH_2$ -ester), 168.65 (C=O, ester), 76.36 (C-1), 31.94 (C-2), 23.16 (C-3), 116.50 (C-4), 127.25 (C-5), 100.98 (C-6), 154.92 (C-7), 100.16 (C-8), 154.65 (C-9), 140.34 (C-10), 91.35 (C-11), 40.35 (C-12), 114.75 (C-13), 147.56 (C-14), 142.32 (C-15), 128.86 (C-16, C-20), 128.08 (C-17, C-19), 125.46 (C-18), 158.80 (C-21), 48.56 (C-22); MS (EI, 70 eV):  $m/z$  = 504 [ $M^+$ , 8] and at 191 (100, base peak). Anal. calcd. for  $C_{28}H_{29}N_3O_6$  (503.54): C, 66.79; H, 5.80; N, 8.34. Found: C, 66.72; H, 5.74; N, 8.30.

*2-(5-(Aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-acetohydrazides (7a,b)*

A mixture of the ester **6a** or **6b** (0.05 mol) and hydrazine hydrate (2.5 g, 0.05 mol) in ethanol (20 ml) was stirred for 2 h at room temperature. Excess ethanol was evaporated under vacuum, and the obtained precipitate product was filtered off, dried, and crystallized from ethanol to give compounds **7a,b**.

*2-(5-(4-Hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetohydrazide (7a)*

Yield 77 %, m.p. 231 °C; IR (KBr,  $cm^{-1}$ ): 3380 (OH), 3311–3300 (N–H str), 3070 (CH Ar.), 2957 (C–H aliph.), 1680, 1662 (C=O), 1577 (N–H bending scissoring).  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.46 (d, 6H,  $2CH_3$ ), 1.96–2.43 (m, 4H,  $2CH_2$ ), 3.80, 3.92 (2s, 6H,  $2OCH_3$ ), 4.32 (s, 2H,  $NH_2$ , exchangeable with  $D_2O$ ), 4.45 (s, 1H, CH-pyrane), 4.86 (s, 2H,  $CH_2$ ), 5.70 (s, 1H, OH exchangeable with  $D_2O$ ), 6.88–7.72 (m, 6H, Ar–H + CH-pyrane), 10.30

(s, 1H, NH exchangeable with  $D_2O$ );  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.12 ( $2CH_3$ ), 56.25, 56.42 ( $2OCH_3$ ), 169.48 (C=O, hydrazide), 76.18 (C-1), 32.08 (C-2), 23.24 (C-3), 117.62 (C-4), 127.32 (C-5), 101.05 (C-6), 155.02 (C-7), 100.12 (C-8), 154.52 (C-9), 140.30 (C-10), 92.00 (C-11), 40.32 (C-12), 115.05 (C-13), 146.98 (C-14), 135.42 (C-15), 122.16 (C-16), 115.58 (C-17), 142.02 (C-18), 151.18 (C-19), 114.26 (C-20), 159.02 (C-21), 48.55 (C-22); MS (EI, 70 eV):  $m/z$  = 536 [ $M^+$ , 16] and at 314 (100, base peak). Anal. calcd. for  $C_{27}H_{29}N_5O_7$  (535.54): C, 60.55; H, 5.46; N, 13.08. Found: C, 60.48; H, 5.40; N, 13.00.

*2-(7-(7-Methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetohydrazide (7b)*

Yield: 80 %, m.p. 228 °C; IR (KBr,  $cm^{-1}$ ): 3311–3300 (N–H str), 3070 (CH Ar.), 2957 (C–H aliph.), 1680, 1662 (C=O), 1577 (N–H bending scissoring);  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.50 (d, 6H,  $2CH_3$ ), 2.00–2.44 (m, 4H,  $2CH_2$ ), 3.90 (s, 3H,  $OCH_3$ ), 4.36 (s, 2H,  $NH_2$ , exchangeable with  $D_2O$ ), 4.45 (s, 1H, CH-pyrane), 4.78 (s, 2H,  $CH_2$ ), 6.85–7.76 (m, 8H, Ar–H + CH-pyrane), 10.30 (s, 1H, NH exchangeable with  $D_2O$ );  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.48 ( $2CH_3$ ), 56.15 ( $OCH_3$ ), 169.64 (C=O, hydrazide), 76.42 (C-1), 31.95 (C-2), 23.15 (C-3), 116.52 (C-4), 127.22 (C-5), 106.00 (C-6), 154.95 (C-7), 100.18 (C-8), 154.63 (C-9), 140.33 (C-10), 92.12 (C-11), 40.32 (C-12), 114.78 (C-13), 147.56 (C-14), 142.35 (C-15), 129.08 (C-16, C-20), 128.34 (C-17, C-19), 125.52 (C-18), 169.80 (C-21), 52.56 (C-22); MS (EI, 70 eV):  $m/z$  = 490 [ $M^+$ , 12] and at 184 (100, base peak). Anal. calcd. for  $C_{26}H_{27}N_5O_5$  (489.52): C, 63.79; H, 5.56; N, 14.31. Found: C, 63.74; H, 5.50; N, 14.24.

*2-(5-(Aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N'-(5,5-dimethyl-3-oxocyclohex-1-enyl)acetohydrazides (8a,b)*

A mixture of equimolar amounts of 5,5-dimethyl-1, 3-cyclohexadione (dimedone) and hydrazides **7a,b** (0.05 mol) in toluene (15 ml) was heated under reflux for 4 h. using Dean-Stark water separator. After cooling, the obtained crystalline product was filtered off, dried, and recrystallized from toluene to give compounds **8a,b**, respectively.

*2-(5-(4-Hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N'-(5,5-dimethyl-3-oxocyclohex-1-enyl)acetohydrazide (8a)*

Yield: 70 %, m.p. 248 °C; IR (KBr,  $cm^{-1}$ ): 3380 (OH), 3197 (2N–H str), 3010 (CH-Ar), 2957 (C–H Aliph.), 1710,

1750, 1690 (C=O), 1583 (N–H bending scissoring);  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 0.97, 1.02 (2s, 6H, 2CH<sub>3</sub>), 1.48 (d, 6H, 2CH<sub>3</sub>), 1.88–2.44 (m, 8H, 4CH<sub>2</sub>), 3.80, 4.10 (2s, 6H, 2OCH<sub>3</sub>), 4.42 (s, 1H, CH-pyrane), 5.84 (s, 1H, OH exchangeable with D<sub>2</sub>O), 5.20 (s, 2H, N–CH<sub>2</sub>), 5.42 (s, 1H, CH cyclohexene), 7.40–7.72 (m, 6H, Ar–H + CH-pyrane), 8.80 (s, 1H, NH exchangeable with D<sub>2</sub>O), 10.30 (s, 1H, NH, NH exchangeable with D<sub>2</sub>O);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 26.85 (2CH<sub>3</sub>), 27.50 (2CH<sub>3</sub>), 56.10, 56.15 (2OCH<sub>3</sub>), 76.35 (C-1), 31.95 (C-2), 23.15 (C-3), 116.86 (C-4), 127.18 (C-5), 100.86 (C-6), 154.98 (C-7), 100.20 (C-8), 154.62 (C-9), 140.30 (C-10), 91.32 (C-11), 40.31 (C-12), 115.75 (C-13), 146.56 (C-14), 135.00 (C-15), 119.80 (C-16), 116.08 (C-17), 142.15 (C-18), 151.05 (C-19), 113.85 (C-20), 158.60 (C-21), 54.50 (C-22), 169.65 (C-23), 162.80 (C-24), 101.80 (C-25), 197.90 (C-26), 53.82 (C-27), 32.67 (C-28), 40.08 (C-29); MS (EI, 70 eV):  $m/z$  = 658 [ $\text{M}^+$ , 32] and at 286 (100, base peak). Anal. calcd. for C<sub>35</sub>H<sub>39</sub>N<sub>5</sub>O<sub>8</sub> (657.71): C, 63.91; H, 5.98; N, 10.65. Found: C, 63.86; H, 5.92; N, 10.60.

2-(7-(7-Methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-*d*][1,2,3]triazin-3(5H)-yl)-*N*'-(5,5-dimethyl-3-oxocyclohex-1-enyl)acetohydrazide (**8b**)

Yield: 75 %, m.p. 253 °C; IR (KBr, cm<sup>−1</sup>): 3197 (2 N–H str), 3010 (CH–Ar), 2957 (C–H aliph.), 1710, 1750, 1690 (C=O), 1583 (N–H bending scissoring);  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 0.97, 1.04 (2s, 6H, 2CH<sub>3</sub>), 1.55 (d, 6H, 2CH<sub>3</sub>), 1.95–2.50 (m, 8H, 4CH<sub>2</sub>), 3.90 (s, 3H, OCH<sub>3</sub>), 4.46 (s, 1H, CH-pyrane), 5.18 (s, 2H, N–CH<sub>2</sub>), 5.46 (s, 1H, CH cyclohexene), 7.40–7.72 (m, 8H, Ar–H + CH-pyrane), 8.80 (s, 1H, NH, exchangeable with D<sub>2</sub>O), 10.30 (s, 1H, NH, exchangeable with D<sub>2</sub>O);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 26.86 (2CH<sub>3</sub>), 27.44 (2CH<sub>3</sub>), 56.14 (OCH<sub>3</sub>), 76.42 (C-1), 31.94 (C-2), 23.18 (C-3), 116.84 (C-4), 127.20 (C-5), 100.90 (C-6), 154.96 (C-7), 100.15 (C-8), 154.60 (C-9), 140.33 (C-10), 91.36 (C-11), 40.30 (C-12), 115.70 (C-13), 146.50 (C-14), 142.00 (C-15), 129.09 (C-16, C-20), 128.12 (C-17, C-19), 125.15 (C-18), 158.56 (C-21), 53.96 (C-22), 169.72 (C-23), 162.88 (C-24), 101.84 (C-25), 197.85 (C-26), 53.65 (C-27), 32.12 (C-28), 40.15 (C-29); MS (EI, 70 eV):  $m/z$  = 612 [ $\text{M}^+$ , 24] and at 181 (100, base peak). Anal. calcd. for C<sub>34</sub>H<sub>37</sub>N<sub>5</sub>O<sub>6</sub> (611.68): C, 66.76; H, 6.10; N, 11.45. Found: C, 66.72; H, 6.05; N, 11.40.

*N*-(3-Amino-2-cyano-5,6,7,8-tetrahydro-7,7-dimethyl-4-(4-nitrophenyl)-5-oxoquinolin-1(4H)-yl)-2-(7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-*d*][1,2,3]triazin-3(5H)-yl)acetamide (**9**)

A mixture of equimolar amounts of enaminones **8b** and 2-(4-nitrobenzylidene)malononitrile (0.001 mol) in

ethanol (15 ml) containing four drops of trimethylamine was heated under reflux for 12 h. The reaction mixture was cooled, and the separated solid product was filtered off, washed with water, and crystallized from ethanol to give compound **9**. Yield: 65 %, m.p. 278 °C; IR (KBr, cm<sup>−1</sup>): 3446–3341 (NH<sub>2</sub>, str), 3020 (C–H Ar.), 2958 (C–H Aliph.), 1750, 1690 (C=O), 1650 (C=C conj), 2184 (CN);  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 0.80, 1.06 (2s, 6H, 2CH<sub>3</sub>), 1.52 (d, 6H, 2CH<sub>3</sub>), 2.02–2.45 (m, 8H, 4CH<sub>2</sub>), 3.90 (s, 3H, OCH<sub>3</sub>), 4.48 (s, 1H, CH-pyrane), 4.56 (s, 1H, pyridine-H), 5.20 (s, 2H, N–CH<sub>2</sub>), 6.63 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 6.78 (d, 1H, pyrane-H), 7.05–8.10 (m, 11H, Ar–H), 11.20 (s, 1H, NH, exchangeable with D<sub>2</sub>O);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 26.95 (2CH<sub>3</sub>), 27.45 (2 CH<sub>3</sub>), 56.18 (OCH<sub>3</sub>), 115.04 (C≡N), 76.45 (C-1), 32.00 (C-2), 23.15 (C-3), 116.84 (C-4), 127.14 (C-5), 100.95 (C-6), 155.00 (C-7), 100.10 (C-8), 154.54 (C-9), 140.32 (C-10), 91.32 (C-11), 40.20 (C-12), 115.71 (C-13), 146.51 (C-14), 142.01 (C-15), 129.07 (C-16, C-16'), 128.14 (C-17, C-17'), 125.15 (C-18), 158.58 (C-19), 53.95 (C-20), 169.68 (C-21), 81.01 (C-22), 136.70 (C-23), 35.88 (C-24), 111.80 (C-25), 198.78 (C-26), 52.00 (C-27), 31.95 (C-28), 38.52 (C-29), 145.44 (C-30), 147.65 (C-31), 129.18 (C-32, C-32'), 120.76 (C-33, C-33'), 145.05 (C-34); MS (EI, 70 eV):  $m/z$  = 811 [ $\text{M}^+$ , 14] and at 458 (100, base peak). Anal. calcd. for C<sub>44</sub>H<sub>42</sub>N<sub>8</sub>O<sub>8</sub> (810.85): C, 65.17; H, 5.22; N, 13.82. Found: C, 65.14; H, 5.18; N, 13.80.

*N*-(1,2,3,4,5,6,7,8-Octahydro-3,3,6,6-tetramethyl-9-(4-nitrophenyl)-1,8-dioxoacridin-10(9H)-yl)-2-(7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-*d*][1,2,3]triazin-3(5H)-yl)acetamide (**10**)

A mixture of two molar amounts of enaminone **8b** and 2-(4-nitrobenzylidene) malononitrile (0.001 mol) was refluxed in glacial acetic acid (20 ml) for 3 h with few drops of trimethylamine. The reaction mixture was concentrated under vacuum, and the solid formed after cooling was collected by filtration, dried, and crystallized from aqueous ethanol to give compound **10**. Yield: 60 %, m.p. 288 °C; IR (KBr, cm<sup>−1</sup>): 3020 (C–H Ar.), 2958 (C–H aliph), 1750, 1690 (C=O), 1650 (C=C conj).  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 0.82, 1.06 (2s, 6H, 2CH<sub>3</sub>), 1.52 (d, 6H, 2CH<sub>3</sub>), 1.98–2.52 (m, 12H, 6CH<sub>2</sub>), 3.90 (s, 3H, OCH<sub>3</sub>), 4.42 (s, 1H, CH-pyrane), 4.62 (s, 1H, pyridine-H), 5.16 (s, 2H, N–CH<sub>2</sub>), 6.64 (d, 1H, pyrane-H), 7.15–8.04 (m, 11H, Ar–H), 11.20 (s, 1H, NH, exchangeable with D<sub>2</sub>O);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 26.88 (2CH<sub>3</sub>), 27.42 (4CH<sub>3</sub>), 56.34 (OCH<sub>3</sub>), 76.44 (C-1), 32.01 (C-2), 23.16 (C-3), 116.85 (C-4), 127.13 (C-5), 100.90 (C-6), 155.02 (C-7), 100.13 (C-8), 154.55 (C-9), 140.34 (C-10), 91.32 (C-11), 40.24 (C-12), 115.70 (C-13), 146.50 (C-14), 142.04 (C-15), 129.08 (C-16, C-16'), 128.15 (C-17, C-17'), 125.18 (C-18),

158.60 (C-19), 53.92 (C-20), 169.64 (C-21), 145.52 (C-22, C-34), 38.74 (C-23, C-33), 31.65 (C-24, C-32), 51.32 (C-25, C-31), 198.82 (C-26, C-30), 111.45 (C-27, C-29), 41.02 (C-28), 148.13 (C-35), 129.76 (C-36, C-36'), 120.65 (C-37, C-37'), 145.30 (C-38); MS (EI, 70 eV):  $m/z$  = 867 [ $M^+$ , 10] and at 436 (100, base peak). Anal. calcd. for  $C_{49}H_{50}N_6O_9$  (866.95): C, 67.88; H, 5.81; N, 9.69. Found: C, 67.82; H, 5.80; N, 9.64.

*1-(2-(5-(Aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetyl)-4-phenylthiosemicarbazide (11a,b)*

A mixture of compound **7a** or **7b** (0.012 mol) and phenylisothiocyanate (0.012 mol, 1.62 g) in ethanol (15 ml) was refluxed for 1 h. After cooling, the obtained precipitate was filtered off, dried, and crystallized from ethanol to give compounds **11a** or **11b**.

*1-(2-(5-(4-Hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetyl)-4-phenylthiosemicarbazide (11a)*

Yield: 76 %, m.p. 261 °C; IR (KBr,  $cm^{-1}$ ): 3380 (OH), 3331, 3227, 3219 (N–H str), 3050 (CH–Ar.), 2931 (C–H aliph), 1740, 1684 (C=O), 1570 (N–H bending scissoring), 1300 (C=S).  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.52 (d, 6H, 2CH<sub>3</sub>), 1.94–2.45 (m, 4H, 2CH<sub>2</sub>), 3.80, 4.10 (2s, 6H, 2OCH<sub>3</sub>), 4.45 (s, 1H, CH-pyrane), 5.12 (s, 2H, N–CH<sub>2</sub>), 5.70 (s, 1H, OH exchangeable with D<sub>2</sub>O), 6.65 (d, 1H, CH-pyrane), 7.72–8.00 (m, 10H, Ar–H), 9.76, 10.01, 10.50 (3s, 3H, 3NH, exchangeable with D<sub>2</sub>O);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.12 (2CH<sub>3</sub>), 56.25, 56.42 (2OCH<sub>3</sub>), 179.48 (C=S), 76.18 (C-1), 32.10 (C-2), 23.24 (C-3), 117.63 (C-4), 127.30 (C-5), 101.08 (C-6), 155.00 (C-7), 100.12 (C-8), 154.50 (C-9), 140.30 (C-10), 92.00 (C-11), 40.32 (C-12), 115.07 (C-13), 146.94 (C-14), 135.43 (C-15), 121.96 (C-16), 116.08 (C-17), 142.12 (C-18), 151.18 (C-19), 114.26 (C-20), 159.02 (C-21), 48.55 (C-22), 169.10 (C-23), 136.96 (C-24), 126.36 (C-25, C-25'), 128.75 (C-26, C-26'), 124.10 (C-27); MS (EI, 70 eV):  $m/z$  = 670 [ $M^+$ , 26] and at 194 (100, base peak). Anal. calcd. for  $C_{34}H_{34}N_6O_7S$  (670.73): C, 60.85; H, 5.11; N, 12.53, S, 4.78; Found: C, 60.80; H, 5.06; N, 12.48; S, 4.73.

*1-(2-(7-(7-Methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)acetyl)-4-phenylthiosemicarbazide (11b)*

Yield: 70 %, m.p. 266 °C; IR (KBr,  $cm^{-1}$ ): 3331, 3227, 3219 (N–H str), 3050 (CH–Ar.), 2931 (C–H Aliph.), 1740, 1684 (C=O), 1570 (N–H bending scissoring), 1300 (C=S);

$^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.50 (d, 6H, 2CH<sub>3</sub>), 2.02–2.48 (m, 4H, 2CH<sub>2</sub>), 3.86 (s, 1H, OCH<sub>3</sub>), 4.44 (s, 1H, CH-pyrane), 5.12 (s, 2H, N–CH<sub>2</sub>), 6.74 (s, 1H, CH-pyrane), 7.25–8.05 (m, 12H, Ar–H), 9.80, 10.05, 10.45 (3s, 3H, 3NH, exchangeable with D<sub>2</sub>O);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.48 (2CH<sub>3</sub>), 56.15 (OCH<sub>3</sub>), 179.45 (C=S), 76.36 (C-1), 31.98 (C-2), 23.16 (C-3), 116.54 (C-4), 127.26 (C-5), 106.05 (C-6), 154.92 (C-7), 100.13 (C-8), 154.65 (C-9), 140.35 (C-10), 92.13 (C-11), 40.34 (C-12), 114.76 (C-13), 147.58 (C-14), 142.31 (C-15), 129.01 (C-16, C-20), 128.31 (C-17, C-19), 125.51 (C-18), 169.81 (C-21), 52.51 (C-22), 169.00 (C-23), 136.92 (C-24), 126.37 (C-25, C-25'), 128.76 (C-26, C-26'), 124.12 (C-27); MS (EI, 70 eV):  $m/z$  = 624 [ $M^+$ , 18] and at 194 (100, base peak). Anal. calcd. for  $C_{33}H_{32}N_6O_5S$  (624.70): C, 63.45; H, 5.16; N, 13.45; S, 5.13. Found: C, 63.40; H, 5.10; N, 13.40; S, 5.90.

*(30Z)-2-(5-(Aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N'-(3,4-diphenylthiazol-2(3H)-ylidene)acetohydrazides (12a,b)*

A mixture of compound **11a** or **11b** (0.001 mol), phenacylbromide (0.233 g, 0.001 mol), and fused sodium acetate (0.238 g, 0.004 mol) in absolute ethanol (10 ml) was heated under reflux for 10 h with stirring. The reaction mixture was cooled and diluted with water, and the separated product was filtered off, dried, and crystallized from ethanol to give compounds **12a** or **12b**.

*(30Z)-2-(5-(4-Hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano [2,3-d][1,2,3]triazin-3(5H)-yl)-N'-(3,4-diphenylthiazol-2(3H)-ylidene)acetohydrazide (12a)*

Yield: 72 %, m.p. 283 °C; IR (KBr,  $cm^{-1}$ ): 3380 (OH), 3242 (N–H str), 1715, 1750, 1680 (C=O), 3050 (CH Ar.);  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.54 (d, 6H, 2CH<sub>3</sub>), 1.96–2.44 (m, 4H, 2CH<sub>2</sub>), 3.78, 4.08 (s, 6H, 2OCH<sub>3</sub>), 4.46 (s, 1H, CH-pyrane), 5.13 (s, 2H, N–CH<sub>2</sub>), 5.76 (s, 1H, OH exchangeable with D<sub>2</sub>O), 6.52 (s, 1H, CH thiazole), 6.72–7.55 (m, 16H, Ar–H + CH-pyrane), 10.50 (s, 1H, NH exchangeable with D<sub>2</sub>O);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.24 (2CH<sub>3</sub>), 56.18, 56.28 (2OCH<sub>3</sub>), 76.34 (C-1), 31.93 (C-2), 23.22 (C-3), 116.54 (C-4), 127.28 (C-5), 101.06 (C-6), 155.08 (C-7), 99.98 (C-8), 154.60 (C-9), 140.30 (C-10), 91.44 (C-11), 40.42 (C-12), 114.74 (C-13), 147.56 (C-14), 135.36 (C-15), 121.86 (C-16), 116.12 (C-17), 142.24 (C-18), 151.16 (C-19), 114.24 (C-20), 158.75 (C-21), 48.56 (C-22), 168.68 (C-23), 156.70 (C-24), 148.05 (C-25), 106.65 (C-26), 141.60 (C-27), 116.02 (C-28, C-28'), 129.52 (C-29, C-29'), 118.95 (C-30), 135.01

(C-31), 126.68 (C-32, C-32'), 128.78 (C-33, C-33'), 127.82 (C-34); MS (EI, 70 eV):  $m/z = 771$  [ $M^+$ , 22] and at 266 (100, base peak). Anal. calcd. for  $C_{42}H_{38}N_6O_7S$  (770.85): C, 65.44; H, 4.97; N, 10.90; S, 4.16. Found: C, 65.40; H, 4.92; N, 10.86; S, 4.12.

(30Z)-2-(7-(7-Methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N'-(3,4-diphenylthiazol-2(3H)-ylidene)acetohydrazide (**12b**)

Yield: 75 %, m.p. 270 °C; IR (KBr,  $cm^{-1}$ ): 3242 (N-H str), 1715, 1750, 1680 (C=O), 3050 (CH Ar);  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta = 1.49$  (d, 6H, 2CH<sub>3</sub>), 2.04–2.46 (m, 4H, 2CH<sub>2</sub>), 3.86 (s, 3H, OCH<sub>3</sub>), 4.48 (s, 1H, CH-pyrane), 5.16 (s, 2H, N-CH<sub>2</sub>), 6.45 (s, 1H, CH thiazole), 6.78–7.58 (m, 18H, Ar-H + CH-pyrane), 10.46 (s, 1H, NH, exchangeable with D<sub>2</sub>O);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta = 27.52$  (2CH<sub>3</sub>), 56.18 (OCH<sub>3</sub>), 76.38 (C-1), 31.94 (C-2), 23.18 (C-3), 116.50 (C-4), 127.25 (C-5), 100.96 (C-6), 154.92 (C-7), 100.16 (C-8), 154.65 (C-9), 140.30 (C-10), 91.33 (C-11), 40.35 (C-12), 114.75 (C-13), 147.56 (C-14), 142.32 (C-15), 128.86 (C-16, C-20), 128.05 (C-17, C-19), 125.42 (C-18), 158.82 (C-21), 48.54 (C-22), 168.65 (C-23), 156.68 (C-24), 148.00 (C-25), 106.60 (C-26), 141.55 (C-27), 116.00 (C-28, C-28'), 129.50 (C-29, C-29'), 118.92 (C-30), 135.00 (C-31), 126.64 (C-32, C-32'), 128.75 (C-33, C-33'), 127.85 (C-34); MS (EI, 70 eV):  $m/z = 725$  [ $M^+$ , 28] and at 268 (100, base peak). Anal. calcd. for  $C_{41}H_{36}N_6O_5S$  (724.82): C, 67.90; H, 5.05; N, 11.59; S, 4.42. Found: C, 67.85; H, 5.00; N, 11.54; S, 4.38.

2-(5-(Aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N-(2,5-dimethyl-1H-pyrrol-1-yl)acetamide (**13a,b**)

A mixture of hydrazide **7a** or **7b** (0.002 mol) and 2,5-hexanedione (0.25 ml, 0.002 mol) in glacial acetic acid (5 ml) was stirred at room temperature overnight. The reaction mixture was poured onto water, and the separated solid was filtered off, dried, and crystallized from ethanol to give compounds **13a,b**, respectively.

2-(5-(4-Hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N-(2,5-dimethyl-1H-pyrrol-1-yl)acetamide (**13a**)

Yield: 82 %, m.p. 268 °C; IR (KBr,  $cm^{-1}$ ): 3380 (OH), 3284 (N-H str), 3067 (C-H Ar), 2978 (C-H aliph.), 1750, 1681 (C=O), 1582 (N-H bending scissoring);  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta = 1.48$  (d, 6H, 2CH<sub>3</sub>), 1.95 (s, 6H, 2CH<sub>3</sub>), 2.08–2.42 (m, 4H, 2CH<sub>2</sub>), 3.80, 4.10 (2s, 6H,

2OCH<sub>3</sub>), 4.42 (s, 1H, CH-pyrane), 5.18 (s, 2H, N-CH<sub>2</sub>), 5.74 (s, 1H, OH exchangeable with D<sub>2</sub>O), 6.56 (d, 2H, 2CH pyrrole), 6.68–7.72 (m, 6H, Ar-H + CH-pyrane), 11.14 (s, 1H, NH exchangeable with D<sub>2</sub>O);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta = 12.54$  (2CH<sub>3</sub>), 27.32 (2CH<sub>3</sub>), 56.13, 56.16 (2OCH<sub>3</sub>), 76.42 (C-1), 31.90 (C-2), 23.12 (C-3), 116.82 (C-4), 127.19 (C-5), 100.85 (C-6), 154.95 (C-7), 100.23 (C-8), 154.63 (C-9), 140.29 (C-10), 91.35 (C-11), 40.34 (C-12), 115.71 (C-13), 146.51 (C-14), 135.01 (C-15), 119.81 (C-16), 116.08 (C-17), 142.15 (C-18), 151.06 (C-19), 113.86 (C-20), 158.62 (C-21), 54.51 (C-22), 170.65 (C-23), 132.80 (C-24, C-24'), 105.80 (C-25, C-25'); MS (EI, 70 eV):  $m/z = 614$  [ $M^+$ , 12] and at 138 (100, base peak). Anal. calcd. for  $C_{33}H_{35}N_5O_7$  (613.66): C, 64.59; H, 5.75; N, 11.41. Found: C, 64.56; H, 5.71; N, 11.36.

2-(7-(7-Methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N-(2,5-dimethyl-1H-pyrrol-1-yl)acetamide (**13b**)

Yield: 80 %, m.p. 263 °C; IR (KBr,  $cm^{-1}$ ): 3284 (N-H str), 3067 (C-H Ar), 2978 (C-H aliph.), 1750, 1681 (C=O), 1582 (N-H bending scissoring);  $^1H$ -NMR (DMSO- $d_6$ , ppm):  $\delta = 1.50$  (d, 6H, 2CH<sub>3</sub>), 1.94 (s, 6H, 2CH<sub>3</sub>), 2.05–2.46 (m, 4H, 2CH<sub>2</sub>), 3.86 (s, 3H, OCH<sub>3</sub>), 4.48 (s, 1H, CH-pyrane), 5.10 (s, 2H, N-CH<sub>2</sub>), 6.58 (d, 2H, 2CH pyrrole), 6.64–7.78 (m, 8H, Ar-H + CH-pyrane), 10.50 (s, 1H, NH exchangeable with D<sub>2</sub>O);  $^{13}C$ -NMR (DMSO- $d_6$ , ppm):  $\delta = 13.08$  (2CH<sub>3</sub>), 27.44 (2CH<sub>3</sub>), 56.14 (OCH<sub>3</sub>), 76.44 (C-1), 31.95 (C-2), 23.19 (C-3), 116.84 (C-4), 127.20 (C-5), 100.90 (C-6), 154.96 (C-7), 99.96 (C-8), 154.61 (C-9), 140.33 (C-10), 91.35 (C-11), 40.31 (C-12), 115.71 (C-13), 146.51 (C-14), 142.01 (C-15), 129.05 (C-16, C-20), 128.15 (C-17, C-19), 125.17 (C-18), 158.59 (C-21), 53.93 (C-22), 170.68 (C-23), 132.77 (C-24, C-24'), 106.09 (C-25, C-25'); MS (EI, 70 eV):  $m/z = 568$  [ $M^+$ , 16] and at 137 (100, base peak). Anal. calcd. for  $C_{32}H_{33}N_5O_5$  (567.63): C, 67.71; H, 5.86; N, 12.34. Found: C, 67.65; H, 5.82; N, 12.28.

2-(5-(Aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N-(1,3-dioxoisindolin-2-yl)acetamide (**14a,b**)

A mixture of hydrazides **7a,b** (0.002 mol) and phthalic anhydride (0.296 g, 0.002 mol) in absolute ethanol (10 ml) with a few drops of glacial acetic acid was refluxed for 6 h. The reaction mixture was concentrated under reduced pressure, and the obtained solid was filtered off, dried, and crystallized from ethanol to give compounds **14a,b**, respectively.



2-(5-(4-Hydroxy-3-methoxyphenyl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N-(1,3-dioxoisindolin-2-yl)acetamide (**14a**)

Yield: 75 %, m.p. 297 °C; IR (KBr,  $\text{cm}^{-1}$ ): 3380 (OH), 3197 (N–H str), 3093 (C–H Ar), 1750, 1727, 1694, 1672 (C=O), 1574 (N–H bending scissoring);  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.54 (d, 6H, 2CH<sub>3</sub>), 1.99–2.42 (m, 4H, 2CH<sub>2</sub>), 3.80, 4.10 (2s, 6H, 2OCH<sub>3</sub>), 4.45 (s, 1H, CH-pyrane), 5.20 (s, 2H, N–CH<sub>2</sub>), 5.72 (s, 1H, OH exchangeable with D<sub>2</sub>O), 6.64 (d, 1H, CH-pyrane), 7.05–8.30 (m, 9H, Ar–H), 11.20 (s, 1H, NH exchangeable with D<sub>2</sub>O);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.34 (2CH<sub>3</sub>), 56.28, 56.30 (2OCH<sub>3</sub>), 76.35 (C-1), 31.95 (C-2), 23.23 (C-3), 116.54 (C-4), 127.25 (C-5), 101.08 (C-6), 155.04 (C-7), 99.92 (C-8), 154.61 (C-9), 140.31 (C-10), 91.46 (C-11), 40.40 (C-12), 114.73 (C-13), 147.59 (C-14), 135.39 (C-15), 121.85 (C-16), 116.13 (C-17), 142.22 (C-18), 151.15 (C-19), 114.26 (C-20), 158.76 (C-21), 48.55 (C-22), 168.65 (C-23), 164.56 (C-24, C-24'), 131.75 (C-25, C-25'), 127.56 (C-26, C-26'), 123.12 (C-27, C-27'); MS (EI, 70 eV):  $m/z$  = 666 [ $\text{M}^+$ , 36] and at 190 (100, base peak). Anal. calcd. for C<sub>35</sub>H<sub>31</sub>N<sub>5</sub>O<sub>9</sub> (665.64): C, 63.15; H, 4.69; N, 10.52. Found: C, 63.10; H, 4.65; N, 10.46.

2-(7-(7-Methoxy-2,2-dimethylchroman-6-yl)-4-oxo-5-phenyl-4H-pyrano[2,3-d][1,2,3]triazin-3(5H)-yl)-N-(1,3-dioxoisindolin-2-yl)acetamide (**14b**)

Yield: 78 %, m.p. 307 °C; IR (KBr,  $\text{cm}^{-1}$ ): 3197 (N–H str), 3093 (C–H Ar), 1750, 1727, 1694, 1672 (C=O), 1574 (N–H bending scissoring).  $^1\text{H}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 1.54 (d, 6H, 2CH<sub>3</sub>), 2.00–2.48 (m, 4H, 2CH<sub>2</sub>), 3.90 (s, 3H, OCH<sub>3</sub>), 4.42 (s, 1H, CH-pyrane), 5.14 (s, 2H, N–CH<sub>2</sub>), 6.68 (d, 1H, CH-pyrane), 7.15–8.32 (m, 11H, Ar–H), 11.18 (s, 1H, NH exchangeable with D<sub>2</sub>O);  $^{13}\text{C}$ -NMR (DMSO- $d_6$ , ppm):  $\delta$  = 27.48 (2 CH<sub>3</sub>), 56.18 (OCH<sub>3</sub>), 76.40 (C-1), 31.95 (C-2), 23.18 (C-3), 116.50 (C-4), 127.25 (C-5), 100.96 (C-6), 154.92 (C-7), 100.18 (C-8), 154.65 (C-9), 140.36 (C-10), 91.33 (C-11), 40.36 (C-12), 114.75 (C-13), 147.56 (C-14), 142.30 (C-15), 128.85 (C-16, C-20), 128.06 (C-17, C-19), 125.45 (C-18), 158.81 (C-21), 48.55 (C-22), 168.61 (C-23), 164.55 (C-24, C-24'), 131.72 (C-25, C-25'), 127.50 (C-26, C-26'), 123.12 (C-27, C-27'); MS (EI, 70 eV):  $m/z$  = 620 [ $\text{M}^+$ , 24] and at 190 (100, base peak). Anal. calcd. for C<sub>34</sub>H<sub>29</sub>N<sub>5</sub>O<sub>7</sub> (619.62): C, 65.91; H, 4.72; N, 11.30. Found: C, 65.88; H, 4.70; N, 11.26.

## Anticancer activity


Measurement of cytotoxicity by sulforhodamine B (SRB) assay

Compounds were subjected to a screening system for evaluation of their antitumor activity against liver HEPG2 cancer cell lines in comparison to the known anticancer drugs: 5-FU and DOX. Potential cytotoxicity of the selected derivatives was tested using the method of Skehan *et al.* (1990) as follows: Cells were plated in 96-multiwell plate (104 cells/well) for 24 h before treatment with the compound(s) to allow attachment of cells to the wall of the plate. Different concentrations of the compounds under test (0, 1, 2.5, 5, 10  $\mu\text{g/mL}$ ) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and in an atmosphere of 5 % CO<sub>2</sub>. Cultures were then fixed with trichloroacetic acid and stained for 30 min with 0.4 % (w/v) sulforhodamine B (SRB) dissolved in 1 % acetic acid. Unbound dye was removed by four washes with 1 % acetic acid, and protein-bound dye was extracted with 10 mM-unbuffered Tris base [tris(hydroxymethyl)amino-methane] for determination of optical density in a computer-interfaced, 96-well microtiter plate reader. The SRB assay results were linear with the number of cells and with values for cellular protein measured by both the Lowry and Bradford assays at densities ranging from sparse subconfluence to multilayered supraconfluence. The signal-to-noise ratio at 564 nm was approximately 1.5 with 1,000 cells/well. The relation between surviving fraction and drug concentration was plotted to get the survival curve of both cancer cell lines after the specified compound.

## Result and discussion


### Chemistry

The newly substituted pyrano[1,2,3]triazine derivatives were synthesized by using 1-(2,4-dihydroxyphenyl) ethanone **1** and 1-(7-hydroxy-2,2-dimethylchroman-6-yl)ethanone **2** as starting materials, which were synthesized by reported method (Kumar *et al.*, 2011). The derivative **2** was methylated using methyl iodide in acetone to give 1-(7-methoxy-2,2-dimethylchroman-6-yl)ethanone (**3**), which was treated with aromatic aldehydes in the presence of piperidine to give the corresponding acryloyl derivatives (**4a–c**). Compounds **4a,b** were reacted with ethyl cyanoacetate in pyridine and

**Scheme 1** Synthetic route to compounds **3–7**

gave the corresponding ethyl 2-amino-4-(aryl)-6-(7-methoxy-2,2-dimethylchroman-6-yl)-4*H*-pyran-3-carboxylates (**5a,b**). The diazotization of compounds **5a,b** with sodium nitrite and hydrochloric acid gives unseparated intermediate **[A]**, which was converted to the corresponding esters **6a,b** by reacting with ethyl glycinate hydrochloride. Treatment of ester derivatives **6a,b** with hydrazine hydrate gives the corresponding acid hydrazide derivatives **7a,b** (Scheme 1).

The reaction of compounds **7a,b** with 5,5-dimethyl-1,3-cyclohexanedione afforded the corresponding pyrano[2,3-*d*]1,2,3]triazin-3(5*H*)-yl)-*N'*-(5,5-dimethyl-3-oxocyclohex-1-enyl)acetohydrazide derivatives **8a,b**, respectively. Cyclization of **8b** with 2-(4-nitrobenzylidene)malononitrile (Yao *et al.*, 2008) in ethanol in the presence of few drops of TMA afforded hexahydroquinoline derivative **9**. However, the acridindione **10** was synthesized by heating




**Scheme 2** Synthetic route to compounds **8–10**

of **8b** with 2-(4-nitrobenzylidene)malono-nitrile in acetic acid containing few drops of TMA (Scheme 2).

Treatment of compounds **7a,b** with phenyl isothiocyanate in ethanol gave the corresponding thiosemicarbazide derivatives **11a,b**, respectively, which were cyclized with phenacyl bromide in the presence of sodium acetate to give the corresponding 1,3-thiazole derivatives **12a,b**, respectively. Cyclization of compounds **7a,b** with 2,5-hexanedione in acetic acid affords 2-(5-(aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4*H*-pyrano[2,3-*d*][1,2,3]triazin-3(5*H*)-yl)-*N*-(2,5-dimethyl-1*H*-pyrrol-1-yl)acetamide **13a,b**. Also, the reaction of compounds **7a,b** with phthalic anhydride in acetic acid gave 2-(5-(aryl)-7-(7-methoxy-2,2-dimethylchroman-6-yl)-4-oxo-4*H*-pyrano[2,3-*d*][1,2,3]triazin-3(5*H*)-yl)-*N*-(1,3-dioxoisindolin-2-yl)acetamide **14a,b** (Scheme 3).

#### Anticancer activity

The selected compounds showed reasonable antitumor activity in comparison to 5-FU and DOX. Cytotoxic drugs remain the main stay of cancer chemotherapy and are being administered with novel ways of therapy such as inhibitors of signals (Guilbaud *et al.*, 2001). It is therefore important to discover novel cytotoxic agents with spectra of activity and toxicity that differ from those current agents (El-Nakkady *et al.*, 2012). It is well known that chemotherapy aims to destroy the cancer cells with various types of chemicals (Pautus *et al.*, 2006). The substances used are supposed to target mainly the cancer cells and doses are calculated to minimize the collateral damage to surrounding tissues, which nevertheless occurs (Hayakawa *et al.*, 2004).



**Scheme 3** Synthetic route to compounds **11–14**

This kind of treatment increases the entropy of the organism, suppresses the immune system, and forms a toxic cell environment which may destroy surrounding healthy cells. It is important to use minimum effective doses in a hope to minimize the side effects of chemotherapeutic drugs.

Preliminary screening of the selected derivatives showed that compounds exhibited a moderate to strong

growth inhibition activity on the tested cell line between 1 and 10  $\mu\text{g/mL}$  concentrations in comparison to the known anticancer drugs: 5-FU and DOX. The results in Table 1 indicated the cytotoxic activity of the newly synthesized derivatives (compounds **3**, **4a**, **4b**, **4c**, **5**, **6**, **7**, **8a,b**, **9**, **10**, **11**, **12**, **13**, **14a,b**) on liver HEPG2 cancer cell lines in comparison to the traditional anticancer drugs: 5-FU and DOX. It can be deduced from the results that compounds

**Table 1** Cytotoxicity of the prepared compounds against liver HEPG2 cancer cell lines

Comp. no.	IC <sub>50</sub> [μM]
<b>5-Fluorouracil</b>	0.0380
<b>Doxorubicin</b>	0.00620
<b>3</b>	0.0365
<b>4a</b>	0.0060
<b>4b</b>	0.0075
<b>4c</b>	0.0068
<b>5a</b>	0.0105
<b>5b</b>	0.0112
<b>6a</b>	0.0122
<b>6b</b>	0.0135
<b>7a</b>	0.0272
<b>7b</b>	0.0280
<b>8a</b>	0.0252
<b>8b</b>	0.0270
<b>9</b>	0.0178
<b>10</b>	0.0239
<b>11a</b>	0.0182
<b>11b</b>	0.0195
<b>12a</b>	0.0285
<b>12b</b>	0.0295
<b>13a</b>	0.0442
<b>13b</b>	0.0480
<b>14a</b>	0.0297
<b>14b</b>	0.0350

**4a–c**, **5a,b**, **6a,b**, **9**, and **11a,b** were the most active and induced a reasonable growth inhibition, in a dose-dependent manner against HEPG2 when compared to 5-FU and DOX (IC<sub>50</sub> equals 0.0060, 0.0075, 0.0068, 0.0105, 0.0112, 0.0122, 0.0135, 0.0178, 0.0182, and 0.0195 μM, while for 5-FU and DOX were 0.0380 and 0.00620 μM). Also compounds **11b**, **8a,b**, **7a,b**, **12a,b**, **14a,b**, and **3** were the moderately active and induced a moderate growth inhibition, in a dose-dependent manner against HEPG2 when compared to 5-FU and DOX (IC<sub>50</sub> equals 0.0239, 0.0252, 0.0270, 0.0272, 0.0280, 0.0285, 0.0295, 0.0297, 0.0350, and 0.0365 μM, while for 5-FU and DOX were 0.0380 and 0.00620 μM). Also compounds **13a,b** were the weakly active and induced a little growth inhibition, in a dose-dependent manner against HEPG2 when compared to 5-FU and DOX (IC<sub>50</sub> equals 0.0442 and 0.0480 μM, while for 5-FU and DOX were 0.0380 and 0.00620 μM). From these results, it appeared that compounds **4a–c** > **5a,b** > **6a,b** > **9** > **11a,b** have a strong anticancer activity. Also, compounds **10** > **8a,b** > **7a,b** > **12a,b** > **14a,b** > **3** have a moderate anticancer activity, whereas **13a,b** has weak

anticancer activity. Novel derivatives of pyrano[1,2,3]triazine possessing a broader spectrum of antitumor activity and fewer toxic side effects than 5-FU and DOX have been sought. The antitumor activities of such compounds were assessed against HEPG2 cancer cell line in comparison to the traditional anticancer drugs: 5-FU and DOX.

### Structure–activity relationship (SAR)

It appeared from analysis of the structure of the most strongly active anticancer compounds that compounds **4a–c** have a strong anticancer activities due to the conjugation of enone with aromatic moities; **4a** is the most active due to the presence of OH in para-position (it may be anti-oxidant) then **4c** due to the presence of OCH<sub>3</sub> group. Compounds **5a,b** are active due to the presence of ester (COOEt) and amino (NH<sub>2</sub>) groups, and compounds **6a,b** are active due to the presence of ester group, the activity of **9** due to the presence of amino group and **11b** has C=S and NH-groups. Compound **10** is less active than **9** due to the cyclization of the CN and NH<sub>2</sub> group in **9** and compound **7** is less reactive than **6** due to the changing of the ester group to aceto-hydrazide. Also compound **12** is less active than **11** due to the formation of thiazole ring. And also compound **13** is weak due to the formation of pyrrole ring. Additionally, the difference in activities between the compounds which were due to the indicated substituents in the molecule.

### Conclusion

A series of the newly substituted pyrano[1,2,3]triazine derivatives **3–14** were synthesized using compounds **1** and **2** as starting materials. Some of the synthesized compounds were screened as anticancer agents. All the selected pyrano[1,2,3]triazine derivatives were soluble in DMSO at concentrations high enough to allow cell experiments, and the in vitro biological activity of these compounds was evaluated by their growth inhibitory potency in liver HEPG2 cancer cell lines. The cytotoxic potency of compounds **3–14** was studied in comparison to the known anticancer drugs 5-FU and DOX. The derivatives **4a–c**, **5a,b**, **6a,b**, **9**, and **11a,b** have a strong cytotoxic activity. Also, compounds **10**, **8a,b**, **7a,b**, **12a,b**, **14a,b** > **3** have a moderate cytotoxic activity, whereas compounds **13a,b** have weak cytotoxic activity.

**Acknowledgments** The Authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group Project No. RGP-VPP-0172.

## References

- Abo-Ghalia MH, Amr AE (2004) Synthesis and investigation of a new cyclo-( $N\alpha$ -dipicolinoyl)-pentapeptide of a breast and CNS cytotoxic activity and an ionophoric specificity. *Amino Acids* 26:283–289
- Ahmed FAS, Abdulla MM, Amr AE, Azza AH (2007) Synthesis, reactions, and anti-arrhythmic activity of substituted heterocyclic systems using 5-chloroanisic acid as starting material. *Monat Chem* 138:1019–1027
- Amr AE, Abdalla MM (2006) Anti-inflammatory profile of some synthesized heterocyclic pyridone and pyridine derivatives fused with steroidal structure. *Bioorg Med Chem* 14:4341–4352
- Amr AE, Sayed HH, Abdalla MM (2005) Synthesis and reactions of some new substituted pyridine and pyrimidine derivatives as analgesic, anticonvulsant and antiparkinsonian agents. *Arch Pharm Chem Life Sci* 338:433–440
- Amr AE, Mohamed AM, Mohamed SF, Abdelhafez NA, Hammam AG (2006a) Anticancer activities of some newly synthesized pyridine, pyrane and pyrimidine derivatives. *Bioorg Med Chem* 14:5481–5488
- Amr AE, Nehad AA, Abdalla MM (2006b) Synthesis and antiandrogenic activity of some new 3-substituted androstano[17,16-c]-5'-aryl-pyrazoline and their derivatives. *Bioorg Med Chem* 14:373–384
- Chaudhari JA, Patel RP (2010) Synthesis, characterization, composites fabrication and antimicrobial activity of piperazinyl bisarylhydrazino-s-triazine derivatives. *Int J Chem Tech Res* 2:1949–1954
- El-Nakkady SS, Roaiah HF, El-Serwy WS, Soliman A, Abd El-Moez S, Abdel-Rahman AAH (2012) Antitumor and antimicrobial activities of some hetero aromatic benzofurans derived from naturally occurring visnagin. *Acta Pol Pharm* 69:645–655
- Flefel EM, Salama M, El-Shahat M, El-Hashash MA, El-Faragy AF (2007) A novel synthesis of some new pyrimidine and thiazolopyrimidine derivatives for anticancer evaluation. *Phosphorus Sulfur Silicon Relat Elem* 182:1739–1749
- Gamez P, de Hoog P, Lutz M, Driessen WL, Spek AL, Reedijk J (2003) The new multi-directional polydentate ligand 2,4,6-(dipyridin-2-yl-amino)-[1,3,5]triazine (dpyatriz) can discriminate between Zn(II) and Co(II) nitrate. *Polyhedron* 22:205–210
- Girgis AS, Ahmed-Farag IS (2003) Synthesis of novel 2-alkoxy-5H-benzo[6,7]cyclohepta[1,2-b]pyridine-3-carbonitriles. *Z Naturforsch* 58b:698–703
- Guilbaud NL, Kraus-Berthier F, Meyer-Losic V, Malivet C, Chacun M, Jan F (2001) Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. *Clin Cancer Res* 7:2573–2580
- Halverson F, Hirt RJ (1951) Near ultraviolet solution spectra of the diazines. *J Chem Phys* 19:711–718
- Hammam AG, Fahmy AFM, Amr AE, Mohamed AM (2003) Synthesis of novel tricyclic heterocyclic compounds as potential anticancer agents using chromanone and thiochromanone as synthons. *Indian J Chem* 42B:1985–1993
- Hayakawa I, Shioya R, Agatsuma T, Furukawa H, Naruto S, Sugano Y (2004) A library synthesis of 4-hydroxy-3-methyl-6-phenyl-benzofuran-2-carboxylic acid ethyl ester derivatives as anti-tumor agents. *Bioorg Med Chem Lett* 14:4383–4387
- Jain S, Bhambi D, Sharma R, Talesara L (2007) Synthesis and pharmacological studies of aminoxy containing 2,4,6-trisubstituted-s-triazine derivatives. *Ind J Pharm Sci* 69:28–32
- Karci F, Sener N, Yamaç M, Sener I, Demircali A (2009) The synthesis, antimicrobial activity and absorption characteristics of some novel heterocyclic disazo dyes. *Dyes Pigm* 80:47–52
- Kaswala PB, Chikhahia KH, Shah NK, Patel DP, Patel DH, Mudaliar GV (2009) Design, synthesis and antimicrobial evaluation of s-triazinyl urea and thiourea derivatives. *ARKIVOC* xi:326–335
- Kumar SK, Kanth AV, Reddy KT, Omprakash G (2011) Synthesis and characterization of some novel pyrimidines via Aldol condensation. *J Chem Pharm Res* 3(5):234–252
- Laneri S, Sacchia A, Gallitelli M, Arena F, Luraschi E, Abignente E, Filippelli W, Rossi F (1998) Research on heterocyclic compounds-part XXXIX. 2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic derivatives: synthesis and antiinflammatory activity. *Europ J Med Chem* 33:163–170
- Modha J, Datta N, Parekh H (2001) Synthesis and biological evaluation of some new 3,4-dihydro-pyrimidin-4-ones. *IL Farm* 56:641–646
- Nehad AA, Amr AE, Alhusien AI (2007) Synthesis, reactions and pharmacological screening of heterocyclic derivatives using nicotinic acid as a natural synthon. *Monat Chem* 138:559–567
- Ouf NH, Amr AE (2008) Synthesis and anti-inflammatory activity of some pyrimidines and thienopyrimidines using 1-(2-benzo[d][1,3]dioxol-5-yl)vinyl)-4-mercapto-6-methyl-pyrimidine-5-yl)-ethan-2-one as a starting material. *Monat Chem* 139:579–585
- Ouf NH, Amr AE, Fayed AA (2008) Synthesis, reactions, and pharmacological activities of some pyrimidines using (*N*-methylindolyl) acetic acid as synthon. *Monat Chem* 139:281–287
- Patel RV, Kumari P, Rajani DP, Chikhahia KH (2001) Synthesis and studies of novel 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(quinoline-4-yloxy)-6-(piperazinyl/piperidinyl)-s-triazines as potential antimicrobial, antimycobacterial and anticancer agents. *Europ J Med Chem* 46:4354–4365
- Patel RB, Chikhahia KH, Pannecouque C, Clercq E (2007) Synthesis of novel PETT analogues: 3,4-Dimethoxyphenyl ethyl 1,3,5-triazinylthiourea derivatives and their antibacterial and anti-HIV Studies. *J Braz Chem Soc* 18:312–321
- Patel PV, Patel AB, Kumara P, Chikhahia KH (2012) Synthesis of novel 3-(5-sulfanyl-1,3,4-oxadiazol-2-yl)-2H-chromen-2-one condensed-s-triazinyl piperazines and piperidines as antimicrobial agents. *Med Chem Res* 21:3119–3132
- Pautus S, Yee SW, Jayne M, Coogan MP, Simons C (2006) Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles. *Bioorg Med Chem* 14:3643–3653
- Sharma RGVS, Reddy VM (1993) Synthesis of 1,2-disubstituted-4-[(chromon-3-yl) methylene]-imida-zolin-5(4H)-ones as potential pharmacological agents. *Indian J Heterocycl Chem* 3:111–116
- Shin-ichi Y, Yasuhisa F, Ichiro K, Hisashi Y, Toshiyuki M, Hiroaki G, Takato Y (2006) Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. *J Nat Cancer Inst* 98:456–545
- Skehan P, Storeng R, Scudiero D, Anne AM, McMahon J, Vistica D, Warren JT (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* 82:1107–1112
- Smith JS, Yager PA, Bayer GM (1980) Minimal interferon induction in dogs, using a modified polyribonucleosinic-polyribocytidylic acid complex. *Am J Vet Res* 41:1833–1835
- Srinivas K, Srinivas U, Bhanuprakash K, Harakishore K, Murthy USN, Rao VJ (2006) Synthesis and antibacterial activity of various substituted s-triazines. *Euro J Med Chem* 41:1240–1246
- Vanderhoeck R, Allen G, Settepani JA (1973) Bis(dimethylamino)-s-triazinyl antiinflammatory agents. *J Med Chem* 16:1305–1306
- Yao CS, Lei S, Wang CH, Yu CX, Tu SJ (2008) Solvent-free synthesis of 5-methyl-7-aryl-4,7-dihydro-tetrazolo[1,5-a]pyrimidine-6-carboxylic esters catalyzed by sulfamic acid. *J Heterocycl Chem* 45:1609–1613